Clinical Trial

Clinical Study on Targeted CD19/BCMA CAR-T Therapy for Autoimmune Diseases

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
This is an open clinical pharmacological translational Research Study, aiming to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of RD06-05 in patients with active SLE, SSc, AAV, IIM, NMOSD, MS, MG
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-01-09.
Trial Details
NCT Number NCT06775912
Lead Sponsor Nanjing Bioheng Biotech Co., Ltd.
Conditions SLE, Systemic Sclerosis, IIM, NMOSD, MS, MG, ANCA Associated Vasculitis (AAV)
Enrollment 18 participants
Start Date 2025-01-03
Primary Completion 2027-01-01 (estimated)
Study Completion 2027-06-01 (estimated)
Updated on ClinicalTrials.gov 2026-02-02